A team at the Allen Institute for Brain Science, a division of the Allen Institute, has sent brain samples on a “trip” to gain insights into...
Beckley Psytech has announced the successful completion of its Phase I clinical study of lead candidate BPL-003, a novel benzoate formulation of 5-MeO-DMT.
Colorado has voted to pass the Natural Medicine Health Act (Proposition 122) by 51.4%, which will see the decriminalisation and regulation of the use of psychedelic medicines.
Psychedelic-assisted therapy company Better U has created a Military Liaison Officer position to help expand access for veterans.
Cybin’s CYB004-E Phase 1 trial evaluating DMT has completed dosing for four out of five participant cohorts.
Collaborators of Tryp Therapeutics from the University of Michigan will present two scientific posters at the Society for Neuroscience conference.
How do treatments for mood and anxiety disorders derived from psilocybin exert their effects in the brain?
Awakn has entered into a new partnership agreement with Nushama, one of New York’s leading ketamine-assisted therapy centres.
Beckley Psytech has dosed the first participant in its Phase 1 single-ascending dose (SAD) study of ELE-101 – a novel intravenous formulation of psilocin – with...
Biotechnology company Lusaris Therapeutics – which has a lead programme focusing on DMT for treatment-resistant depression – has launched with its Series A financing of US$60...